FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099630170> ?p ?o ?g. }

• W2099630170 endingPage "4289" @default.
• W2099630170 startingPage "4282" @default.
• W2099630170 abstract "Purpose Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas. Patients and Methods Twenty-two patients with anaplastic gliomas (AG) and 23 patients with glioblastoma (GBM) whose tumors had recurred after radiotherapy and no more than two chemotherapy regimens were enrolled. Fenretinide was given orally on days 1 to 7 and 22 to 28 in 6-week cycles in doses of 600 or 900 mg/m 2 bid. Results Six of 21 (29%) patients in the AG arm and two of 23 (9%) patients in the GBM arm had stable disease at 6 months. One patient with AG treated at 900 mg/m 2 bid dosage had a partial radiologic response. Median progression-free survival (PFS) was 6 weeks for the AG arm and 6 weeks for the GBM arm. PFS at 6 months was 10% for the AG arm and 0% for the GBM arm. Grade 1 or 2 fatigue, dryness of skin, anemia, and hypoalbuminemia were the most frequent toxicities reported. The trial was closed after the first stage because of the inadequate activity at the fenretinide doses used. The first-administration mean plasma C max for fenretinide was 832 ± 360 ng/mL at the 600 mg/m 2 bid dosage and 1,213 ± 261 ng/mL at the 900 mg/m 2 bid dosage. Conclusion Fenretinide was inactive against recurrent malignant gliomas at the dosage used in this trial. However, additional studies using higher doses of the agent are warranted based on the tolerability of the agent and the potential for activity of a higher fenretinide dosage, as suggested in this trial." @default.
• W2099630170 created "2016-06-24" @default.
• W2099630170 creator A5004126746 @default.
• W2099630170 creator A5005194857 @default.
• W2099630170 creator A5006268625 @default.
• W2099630170 creator A5009427059 @default.
• W2099630170 creator A5013054218 @default.
• W2099630170 creator A5014264452 @default.
• W2099630170 creator A5021656597 @default.
• W2099630170 creator A5027150108 @default.
• W2099630170 creator A5033174879 @default.
• W2099630170 creator A5034370633 @default.
• W2099630170 creator A5037535298 @default.
• W2099630170 creator A5038144306 @default.
• W2099630170 creator A5046264008 @default.
• W2099630170 creator A5051168746 @default.
• W2099630170 creator A5058285644 @default.
• W2099630170 creator A5063511816 @default.
• W2099630170 creator A5064593201 @default.
• W2099630170 creator A5064627876 @default.
• W2099630170 creator A5075492015 @default.
• W2099630170 date "2004-11-01" @default.
• W2099630170 modified "2023-10-03" @default.
• W2099630170 title "Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study" @default.
• W2099630170 cites W1495133903 @default.
• W2099630170 cites W1513980229 @default.
• W2099630170 cites W1858109422 @default.
• W2099630170 cites W1858161324 @default.
• W2099630170 cites W1948079440 @default.
• W2099630170 cites W1971101901 @default.
• W2099630170 cites W2005846924 @default.
• W2099630170 cites W2006036234 @default.
• W2099630170 cites W2026608252 @default.
• W2099630170 cites W2028021122 @default.
• W2099630170 cites W2028453270 @default.
• W2099630170 cites W2029445057 @default.
• W2099630170 cites W2064214863 @default.
• W2099630170 cites W2067659186 @default.
• W2099630170 cites W2074401258 @default.
• W2099630170 cites W2093947533 @default.
• W2099630170 cites W2106499939 @default.
• W2099630170 cites W2109364152 @default.
• W2099630170 cites W2112773069 @default.
• W2099630170 cites W2123341322 @default.
• W2099630170 cites W2138077671 @default.
• W2099630170 cites W2139008103 @default.
• W2099630170 cites W2148514473 @default.
• W2099630170 cites W2151172589 @default.
• W2099630170 cites W2157226695 @default.
• W2099630170 cites W2158610635 @default.
• W2099630170 cites W2162269738 @default.
• W2099630170 cites W2321951461 @default.
• W2099630170 cites W2413320270 @default.
• W2099630170 doi "https://doi.org/10.1200/jco.2004.09.096" @default.
• W2099630170 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3820102" @default.
• W2099630170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15514370" @default.
• W2099630170 hasPublicationYear "2004" @default.
• W2099630170 type Work @default.
• W2099630170 sameAs 2099630170 @default.
• W2099630170 citedByCount "78" @default.
• W2099630170 countsByYear W20996301702012 @default.
• W2099630170 countsByYear W20996301702013 @default.
• W2099630170 countsByYear W20996301702014 @default.
• W2099630170 countsByYear W20996301702015 @default.
• W2099630170 countsByYear W20996301702016 @default.
• W2099630170 countsByYear W20996301702017 @default.
• W2099630170 countsByYear W20996301702018 @default.
• W2099630170 countsByYear W20996301702019 @default.
• W2099630170 countsByYear W20996301702020 @default.
• W2099630170 countsByYear W20996301702021 @default.
• W2099630170 countsByYear W20996301702022 @default.
• W2099630170 countsByYear W20996301702023 @default.
• W2099630170 crossrefType "journal-article" @default.
• W2099630170 hasAuthorship W2099630170A5004126746 @default.
• W2099630170 hasAuthorship W2099630170A5005194857 @default.
• W2099630170 hasAuthorship W2099630170A5006268625 @default.
• W2099630170 hasAuthorship W2099630170A5009427059 @default.
• W2099630170 hasAuthorship W2099630170A5013054218 @default.
• W2099630170 hasAuthorship W2099630170A5014264452 @default.
• W2099630170 hasAuthorship W2099630170A5021656597 @default.
• W2099630170 hasAuthorship W2099630170A5027150108 @default.
• W2099630170 hasAuthorship W2099630170A5033174879 @default.
• W2099630170 hasAuthorship W2099630170A5034370633 @default.
• W2099630170 hasAuthorship W2099630170A5037535298 @default.
• W2099630170 hasAuthorship W2099630170A5038144306 @default.
• W2099630170 hasAuthorship W2099630170A5046264008 @default.
• W2099630170 hasAuthorship W2099630170A5051168746 @default.
• W2099630170 hasAuthorship W2099630170A5058285644 @default.
• W2099630170 hasAuthorship W2099630170A5063511816 @default.
• W2099630170 hasAuthorship W2099630170A5064593201 @default.
• W2099630170 hasAuthorship W2099630170A5064627876 @default.
• W2099630170 hasAuthorship W2099630170A5075492015 @default.
• W2099630170 hasBestOaLocation W20996301701 @default.
• W2099630170 hasConcept C104317684 @default.
• W2099630170 hasConcept C126322002 @default.
• W2099630170 hasConcept C143998085 @default.
• W2099630170 hasConcept C185592680 @default.
• W2099630170 hasConcept C2775954498 @default.

• next